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Alcohol and drug abuse take a large toll on society and affected individuals.
However, very few effective treatments are currently available to treat alcohol and
drug addiction. Basic and clinical research has begun to provide some insights into
the underlying neurobiological systems involved in the addiction process. Several
neurotransmitter pathways have been implicated and distinct reward neurocircuitry have
been proposed—including the mesocorticolimbic dopamine (MCL-DA) system and the
extended amygdala. The serotonin (5-HT) neurotransmitter system is of particular interest
and multiple 5-HT receptors are thought to play significant roles in alcohol and drug
self-administration and the development of drug dependence. Among the 5-HT receptors,
the 5-HT7 receptor is currently undergoing characterization as a potential target for
the treatment of several psychiatric disorders. Although this receptor has received
only limited research regarding addictive behaviors, aspects of its neuroanatomical,
biochemical, physiological, pharmacological, and behavioral profiles suggest that it could
play a key role in the addiction process. For instance, genomic studies in humans
have suggested a link between variants in the gene encoding the 5-HT7 receptor
and alcoholism. Recent behavioral testing using high-affinity antagonists in mice and
preliminary tests with alcohol-preferring rats suggest that this receptor could mediate
alcohol consumption and/or reinforcement and play a role in seeking/craving behavior.
Interest in the development of new and more selective pharmacological agents for this
receptor will aid in examining the 5-HT7 receptor as a novel target for treating addiction.
Keywords: serotonin-7 (5-HT7), alcohol abuse, drug abuse, mesocorticolimbic dopamine system, genetics,
pharmacogenetics, selective breeding
INTRODUCTION
The neurotransmitter serotonin (5-HT) plays a major a role in
a number behavioral and psychophysiological functions such as
behavioral inhibition, appetite regulation, mood, cognitive func-
tions, thermoregulation, and addictive behaviors. Relevant to the
present review, dysregulation of the 5-HT system has been impli-
cated as a factor in developing alcohol addiction (Engleman et al.,
2008; Hayes and Greenshaw, 2011; Kirby et al., 2011; Sari, 2013).
For instance, alterations in the 5-HT system are believed to medi-
ate some of alcohol’s effects in rat lines selectively bred for high
alcohol consumption (c.f., Bell et al., 2012) and alcoholic individ-
uals with a polymorphism of the 5-HT transporter can respond
favorably to certain medications (Johnson, 2010; Johnson et al.,
2011). Regarding the effects of alcohol, acute exposure increases
5-HT activity/neurotransmission (McBride et al., 1993; Smith
and Weiss, 1999) but appears to reduce the firing rate (Pistis
et al., 1997) or excitability (Maguire et al., 2014) of 5-HT neu-
rons. It has been suggested that alcohol-induce enhancement of
5-HT release may be due to selective effect on neuronal terminals
(Pistis et al., 1997) whereas alcohol-induced decreases of the
firing rate (Pistis et al., 1997) and excitability (Maguire et al.,
2014) of 5-HT neurons within dorsal raphe nucleus (DRN) may
be selective for somatodendritic region of 5-HT neurons (Pistis
et al., 1997). Chronic exposure of alcohol results in the develop-
ment of tolerance to 5-HT neurotransmission (Smith and Weiss,
1999). In addition, outbred Wistar rats show rapid tolerance
to elevations in mesolimbic extracellular 5-HT levels induced
with systemic ethanol administration (Bare et al., 1998), whereas
alcohol-preferring rats (P-rats) selected for alcohol preference do
not (Thielen et al., 2002). Moreover, alcohol-nonpreferring (NP)
rats selected for alcohol non-preference show no 5-HT response
to ethanol in the same dose range (Thielen et al., 2002). Clinical
and/or pre-clinical studies have reported deficiencies of 5-HT
and/or its major metabolite 5-HIAA in the brains of human
alcoholics (Schmidt et al., 1997; Pivac et al., 2004) and P-rats
(Murphy et al., 1987; Zhou et al., 1991; McBride et al., 1993) as
well as other rats selectively bred for an alcohol preference over
water (c.f., Bell et al., 2012). Pharmacologically, treatments that
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reduce 5-HT neurotransmission can elevate self-administration
of alcohol (Lyness and Smith, 1992; Ciccocioppo et al., 1999),
while treatment with antidepressants that increase 5-HT central
nervous system (CNS) levels reduce craving and withdrawal-
associated behaviors (c.f., Goodman, 2008). Therefore, it has
been proposed that modulation of the 5-HT system is a viable
therapy for alcoholism in a sub-set of patients, suggesting its
role in pharmacogenetics (Johnson, 2004, 2010; Wrase et al.,
2006).
THE 5-HT7R: MOLECULAR STRUCTURE, SYSTEM
TRANSDUCTION, DISTRIBUTION AND PHARMACOLOGICAL
ACTIONS IN THE CNS
There are seven families of 5-HT receptors (5-HT1–7) and at least
14 distinct 5-HT receptor subtypes (Barnes and Sharp, 1999),
which makes the task of understanding the extent to which each
of the 5-HT receptor subtypes mediate addictive behaviors a
complex one. The most recently discovered 5-HT receptor is the
5-HT7 receptor which was identified in 1993 (Bard et al., 1993;
Lovenberg et al., 1993; Ruat et al., 1993). The 5-HT7 receptor
(5-HT7R) has been cloned for the human (Bard et al., 1993), rat
(Lovenberg et al., 1993; Meyerhof et al., 1993; Ruat et al., 1993),
mouse (Plassat et al., 1993), guinea pig (Tsou et al., 1994), and
frog (Nelson et al., 1995). The 5-HT7R is a polypeptide of 448
amino acids in the rat (Ruat et al., 1993). Other studies have
demonstrated that the receptor is constituted of either 404 (Shen
et al., 1993) or 435 amino acids in rats (Lovenberg et al., 1993). It
has been suggested that these differences might be due to the pres-
ence of an intron in the region coding for the secondary putative
boucle (Shen et al., 1993), or the presence of a secondary intron
on the C-terminus of the protein (Ruat et al., 1993). In addi-
tion, studies have revealed the existence of four isoforms of the
5-HT7R in humans and rats, which are produced through alter-
native splicing (Heidmann et al., 1997). Also, the 5-HT7R has a
long C-terminal portion making its homolog sequence with other
cloned receptors limited (<40%) (Meyerhof et al., 1993; Plassat
et al., 1993; Ruat et al., 1993; Shen et al., 1993).
The 5-HT7R is a G-protein-coupled receptor (GPCR) with
positive coupling to adenylate cyclase stimulating the production
of cAMP (Bard et al., 1993; Lovenberg et al., 1993; Ruat et al.,
1993). Parallel research indicated that its activation, in COS-7
or HEK-293 transfected cell lines, induced increases in adeny-
late cyclase activity (Lovenberg et al., 1993; Plassat et al., 1993;
Ruat et al., 1993; Shen et al., 1993). Using RT-PCR analyses, it
has been shown that 5htr7 mRNA is expressed in the forebrain,
brainstem and cerebellum, as well as in the periphery such as the
heart and intestine (Plassat et al., 1993). Northern blot analyses
have demonstrated that 5htr7 mRNA is highly expressed in the
hypothalamus, thalamus, hippocampus, and brainstem; however,
low densities were also found in the cerebral cortex, striatum,
and olfactory tubercle of the guinea pig (Lovenberg et al., 1993;
Meyerhof et al., 1993; Plassat et al., 1993; Ruat et al., 1993; Shen
et al., 1993). Furthermore, ligand binding studies using [3H]-5-
carboxamidotryptamine (5-CT) demonstrated that the receptor
is localized in cortical layers I–III, septum, thalamus, hypotha-
lamus, hippocampus, amygdala, periaqueductal gray matter, and
superior colliculus of the rat (Gustafson et al., 1996).
In general, 5-HT7Rs are highly expressed in specific brain areas
where they are believed to mediate certain behavioral and physi-
ological functions. 5-HT7Rs are expressed in the thalamus (sleep,
epilepsy), hypothalamus (circadian rhythm, thermoregulation,
stress), hippocampus (memory, learning), amygdala (emotional
processes, motivation), and cortex (mood, cognition, sleep) in
humans and rodents (To et al., 1995; Thomas et al., 2002; Martín-
Cora and Pazos, 2004; Varnas et al., 2004; Horisawa et al., 2013).
Autoradiography techniques using [3H]SB-269970 to selectively
label 5-HT7Rs, also found 5-HT7Rs in brainstem nuclei includ-
ing the ventral tegmental area (VTA: reward, addiction), the
dorsal raphe nucleus [DRN: circadian rhythm (along with the
suprachiasmatic nucleus: Lovenberg et al., 1993; Prosser et al.,
1993; Ying and Rusak, 1997; Horikawa et al., 2000; Ehlen et al.,
2001; Yu et al., 2001; Antle et al., 2003; Sprouse et al., 2004) as
well as mood], and the substantia nigra (movement, mood) in
humans (Varnas et al., 2004). A recent autoradiography study
with improved sensitivity in detection of [3H]SB-269970 showed
that 5-HT7Rs are expressed in the nucleus accumbens (ACB:
reward, addiction), substantia nigra and caudate putamen (move-
ment) as well (Horisawa et al., 2013). 5-HT7Rs are localized on
gamma-aminobutyric acid (GABA) interneurons or on gluta-
mate terminals within the CNS (Lovenberg et al., 1993; Harsing
et al., 2004; Hedlund, 2009). Regarding general 5-HT7 recep-
tor function, researchers have found that 5-HT7 receptors are
involved in thermoregulation (Hagan et al., 2000; Thomas et al.,
2003; Hedlund and Sutcliffe, 2004; Matthys et al., 2011), cir-
cadian rhythmicity (Matthys et al., 2011), cognitive functions
(i.e., learning, memory, attention: Yau et al., 2001; Hedlund
and Sutcliffe, 2004; Meneses, 2004), and psychiatric disorders
(i.e., anxiety, depression and psychosis: Guscott et al., 2005;
Hedlund et al., 2005;Wesolowska et al., 2006a,b; Mnie-Filali et al.,
2011).
Since the discovery and successful cloning of 5-HT7 receptors,
several 5-HT7R antagonists and agonists have been developed.
The 5-HT7R has strong affinity for [3H]5-HT, [125I]LSD and 5-
CT (Lovenberg et al., 1993; Meyerhof et al., 1993; Plassat et al.,
1993; Ruat et al., 1993; Shen et al., 1993). These studies also
demonstrated that the receptor has strong affinity for neurolep-
tics, such as (+)butaclamol and clozapine, and antidepressants
suggesting a role in certain psychiatric disorders (Plassat et al.,
1993; Roth et al., 1994; Mullins et al., 1999). The quest for selec-
tive 5-HT7R antagonists (Table 1) has led to the development of
LY215840 (Cushing et al., 1996), SB-258719 (Forbes et al., 1998),
DR4004 (Kikuchi et al., 1999), SB-269970 (Lovell et al., 2000),
and SB-656104-A (Forbes et al., 2002). One of the most useful
5-HT7R antagonists discovered to date is SB269970 which has
been widely used to map 5-HT7R distribution in the brain as
well as studying its functional and behavioral effects. Regarding
5-HT7R agonists, 8-OH-DPAT, which was initially considered a
5-HT1A agonist, was later discovered to also be an effective 5-
HT7R agonist (Dompert et al., 1985; Ruat et al., 1993; Shen et al.,
1993; Hedlund and Sutcliffe, 2004). Subsequently, the need for
more selective agonists (Table 1) led to the development of AS-
19 (Brenchat et al., 2009), MSD-5a, (a partial agonist) (Brenchat
et al., 2009), LP-44 (Leopoldo et al., 2004), LP-12 (Leopoldo
et al., 2007), LP-211 (Leopoldo et al., 2008; Hedlund et al., 2010),
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Table 1 | Representation of 5-HT7 antagonist and agonist that are currently being used in research.
Drug Pharmacology Receptor affinity References
LY215840 Antagonist 5-HTI (Ki = 14.7 nm) 5-HT2A (Ki = 19.6 nm) 5-HT2B (Ki = 1.89 nm)
5-HT2C (Ki = 4.26 nm)
Cushing et al., 1996
S0-258719 Antagonist 5-HT7 (Ki = 31.6 nM) Forbes et al., 1998
DR4004 Antagonist 5-HT7 (pKi = 8.67) 5-HT2A (pKi = 6.84) Kikuchi et al., 1999
SB-269970 Antagonist 5-HT7 (pKi = 8.9) 5-HTI A (pKi < 5) Lovell et al., 2000
SB-656104-A Antagonist 5-HT7 (pKi = 8.7) αlb (pKi < 5) Forbes et al., 2002
8-0H-DPAT Agonist 5-HTIA (Ki = 0.4 nM) 5-HT7 (Ki = 35–52 nM) Dompert et al., 1985; Shen et al., 1993;
Ruat et al., 1993; Hedlund and Sutcliffe,
2004
MSD-5a Partial agonist 5-HT7 (Ki = 0.6 nM) 5-HTIA(Ki = 16 nM) 5-HT2A (Ki = 320 nM) Brenchat et al., 2009
LP-44 Agonist 5-HT7 (Ki = 0.22 nM) 5-HTIA (Ki = 52.7 nM) Leopoldo et al., 2004
LP-12 Agonist 5-HT7 (Ki = 0.13 nM) 5-HTI A (Ki = 60.9 nM) Leopoldo et al., 2007
I.P-211 Agonist 5-HT7 (Ki = 0.58 nM) 5-IITIA (Ki = 188 nM) Leopoldo et al., 2008; Hedlund et al., 2010
AS-19 Agonist 5-HT7 (Ki = 0.6 nM) 5-HTI A (Ki = 89.7 nM) Brenchat et al., 2009
E-55888 Agonist 5-HT7 (Ki = 2.5 nM) 5-HTIA (Ki = 700nM) Brenchat et al., 2009
E-57431 Agonist 5-HT7 (Ki = 0.47 nM), 5-HTID (Ki = 53 nM) 5-HT2A (Ki = 560 nM) Brenchat et al., 2010
E-55888 (Brenchat et al., 2009), and E-57431(Brenchat et al.,
2010).
DOPAMINE AND 5-HT7
The mesocorticolimbic dopamine (MCL-DA) system plays a
major role in reward (natural and drugs of abuse), memory,
learning, motivation and movement. Numerous studies have
reported that activation of the MCL-DA system mediates, at least
in part, alcohol and drug addiction. The MCL system consists of
DA neurons that originate in the VTA and project to the ACB,
amgydala, hippocampus and prefrontal cortex (PFC) (Figure 1).
The raphe nucleus, where 5-HT neurons originate, sends 5-HT
projections to numerous regions including the VTA, ACB, amyg-
dala, hippocampus and PFC (Figure 1). Moreover, studies have
shown that the 5-HT system regulates DA neuronal activity in
these subregions of the MCL system (Azmitia and Segal, 1978;
Parent et al., 1981; Halliday and Törk, 1987; Herve et al., 1987;
Van Bockstaele et al., 1994). For example, 5-HT activates VTA-
DA neurons (Pessia et al., 1994), induces DA release in VTA slices
(Beart and McDonald, 1982), enhances DA release in the ACB
when locally applied to the VTA (Guan and McBride, 1989),
potentiates the excitatory actions of alcohol on VTA-DA neurons
(Brodie et al., 1995), and increases extracellular DA release in the
PFC (Iyer and Bradberry, 1996). In addition, there is evidence
that activation of the dorsal raphe nucleus (DRN) can increase
extracellular levels of DA in the ACB (Yoshimoto and McBride,
1992).
There are only a few studies that have investigated 5-HT7
receptor involvement in DAergic activity. Proliferating neuro-
spheres of mesencephalic precursors are used to observe the
development of cells. SB269970 can increase the generation of
DA neurons in proliferating neurospheres of mesencephalic pre-
cursors, which can be inhibited by cytosine-D-arabinofuranoside
(Ara-C: a cell cycle inhibiter) (Parga et al., 2007). In contrast, a
5-HT7R agonist was shown to block increases in the generation
of DA neurons. Interestingly, double labeling for 5-HT7Rs and
tyrosine hydroxylase (DA marker) showed that 5-HT7Rs do not
appear to be located on DA neurons, whereas double immuno-
labeling for 5-HT7Rs and glial fibrillary acidic protein (GFAP a
marker of astrocytes) or tryptophan hydroxylase (5-HT marker)
showed that 5-HT7Rs are located on glia and serotonergic cells
(Parga et al., 2007). Taken together, these results suggest that
5-HT7Rs are involved in regulating DA neuronal development
following elimination of 5-HT neurons or a reduction of 5-HT
levels (Parga et al., 2007). 5-HT7Rs are also involved in DA neu-
ronal firing activity and DA release. An electrophysiological study
demonstrated that antagonism of 5-HT7Rs with SB269970 pre-
vented amphetamine-induced inhibition of DA neuronal firing in
the VTA (Mnie-Filali et al., 2007). However, administration of a
5-HT7R antagonist alone did not alter the spontaneous activity of
DA neurons (Mnie-Filali et al., 2007). DR4004, a 5-HT7R antag-
onist, can decrease DA and/or 5-HT turnover in the amygdala,
suggesting that 5-HT7 receptors may be located presynaptically
at DA and 5-HT nerve terminals in the amygdala (Takeda et al.,
2005). In other work, Wesolowska and Kowalska (2008) reported
that SB-269970 increased DA, norepinephrine (NE) and 5-HT
efflux in the PFC (Matthys et al., 2011). It has been suggested that
the inhibition of 5-HT7 heteroreceptors on DA and NE neurons
may regulate DA and NE release in the PFC, however there is no
evidence of this co-localization of 5-HT7Rs (Matthys et al., 2011).
Collectively, these studies suggest that activation of 5-HT7Rs may
be involved in early neuronal development of the DAergic system
and may regulate DA release within the MCL-DA system.
GAMMA-AMINOBUTYRIC ACID (GABA) AND 5-HT7
RECEPTORS
Gamma-aminobutyric acid (GABA) is the principal inhibitory
neurotransmitter in the CNS. Research indicates that GABA is
involved in alcohol self-administration, the development of tol-
erance to alcohol’s effects, the genetic risk for developing alcohol
dependence (AD) and the expression of withdrawal-associated
behaviors (Dick and Bierut, 2006; Korpi and Sinkkonen, 2006;
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FIGURE 1 | This illustration depicts the expression of 5-HT7 receptors in
brain structures relevant to addiction. The expression of 5-HT7 receptors
has been found within several areas in the mesocorticolimbic dopamine
(MCL-DA) reward pathway such as ventral tegmental area (VTA), nucleus
accumbens (ACB), amygdala (AMG), hippocampus (HIPP), and prefrontal
cortex (PFC). The solids lines represent DA projections from the VTA to the
ACB, AMG, HIPP, and PFC. The dotted lines represent 5-HT projections from
dorsal raphe nucleus (DRN) to VTA, ACB, AMG, HIPP, and PFC.
Krystal et al., 2006; Kohnke, 2008; Tabakoff et al., 2009; McBride
et al., 2010; Enoch et al., 2012; Herman et al., 2013). Although
there are currently no published studies that have examined
whether 5-HT7Rs mediate these GABAergic effects, it has been
reported that 5HT7Rs are found in the GABAergic system. The
dorsal raphe nucleus (DRN) sends serotonergic projections to
the VTA and ACB and is thought to contribute to addiction
behaviors (Tork, 1990; McBride et al., 1990). It has been sug-
gested that 5-HT7Rs are located on GABA neurons (Duncan
et al., 2001; Glass et al., 2003; Roberts et al., 2004) within the
DRN, but not on the serotonergic neurons themselves (Duncan
et al., 2001). Using in vitro fast cyclic voltammetry, it appears
that GABAergic neurons inhibit neuronal serotonergic activity
and 5-HT release in the DRN (Roberts et al., 2004; Matthys
et al., 2011). Bicuculline, a GABAA antagonist, inhibited SB-
269970 suppression of electrically stimulated 5-HT release in
the DRN, suggesting that 5-HT7R activation may inhibit GABA
interneurons, leading to a decrease in GABA release with a sub-
sequent reduction in inhibitory tone on 5-HT neurons (Roberts
et al., 2004; Matthys et al., 2011). The activation of 5-HT7Rs can
enhance GABAergic transmission in the hippocampus (Tokarski
et al., 2011) and GABAergic neuronal excitability in the globus
pallidus (Chen et al., 2008), whereas 5-HT7Rs in the suprachias-
matic nucleus (SCN) decrease local GABA-dependent excitability
(Kawahara et al., 1994). These findings suggest that 5-HT7Rmod-
ulation of the GABAergic system may vary depending on the
neural substrate examined.
GLUTAMATE AND 5-HT7 RECEPTORS
Glutamate is the principal excitatory neurotransmitter in the
CNS. Alcohol-induced neuroadaptations in glutamate release and
receptor up-regulation (Fadda and Rossetti, 1998) are considered
to be important factors in the development of tolerance to
alcohol’s effects, dependence and withdrawal-associated behav-
iors (Chandler et al., 1998). Research indicates that 5-HT7Rs
regulate the glutamatergic system. The activation of 5-HT7Rs
increases the firing of glutamatergic neurons in the medial pre-
frontal cortex (Fan et al., 2011; Pehrson and Sanchez, 2014)
and hippocampus (Tokarski et al., 2003; Pehrson and Sanchez,
2014). SB269970 administration significantly reduces MK-801-
induced glutamate release in the PFC (Bonaventure et al., 2011).
Antagonism of 5-HT7Rs can also reverse 5-HT agonist-induced
suppression of glutamate release in the DRN and median raphe
nucleus (MRN) (Harsing, 2006; Pehrson and Sanchez, 2014).
It has been suggested that there may be 5-HT7 heterorecep-
tors involved in the inhibition of glutamate release in gluta-
matergic cortico-raphe projections (Harsing, 2006; Duncan and
Congleton, 2010), whereas 5-HT7R enhancement of 5-HT release
may be due to GABA-glutamatergic-serotonergic interactions in
the DRN (Harsing et al., 2004; Roberts et al., 2004; Tokarski
et al., 2012). More recently, Tokarski et al. (2011) have suggested
that 5-HT7R activation may enhance GABAergic transmission in
the hippocampus via presynaptic 5-HT7Rs on excitatory gluta-
matergic input to GABAergic interneurons or activation of post-
synaptic 5-HT7Rs on the GABAergic interneurons themselves.
Given evidence that 5-HT7Rs can modulate glutamatergic output
and the putative role glutamatergic systems play in alcohol and
drug abuse, manipulation of glutamate neurotransmission with
5-HT7R-associated agents may provide an additional mechanistic
approach to develop therapeutic agents targeting addiction.
A ROLE FOR 5-HT7 RECEPTORS IN ALCOHOL AND DRUG
ABUSE
Personality characteristics such as sensation seeking and
impulsivity are linked to an increased risk for drug addiction
behaviors. Sensation-seeking is defined as voluntary participation
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in varied, novel, and intense activities without regard to per-
sonal risk and it is associated with a greater tendency to abuse
drugs and alcohol (Matthys et al., 2011). Ballaz et al. (2007a)
investigated the gene expression of 5htr7 mRNA in an animal
model in which rats were classified as high responders (HR)
that express high levels of novelty seeking and drug-taking
behaviors, or low responders (LR) which express the opposite
phenotype (Zuckerman and Neeb, 1979; Kabbaj, 2006). The
HR rats had significantly lower 5htr7 gene expression in the
dorsal hippocampus, intralaminar nucleus, and paraventricular
thalamic nucleus than the LR rats (Ballaz et al., 2007a). These
results suggest that the low expression of 5htr7 mRNA in HR
rats may be involved in increased novelty seeking behavior
(Hedlund, 2009). In a subsequent study, novel object discrimi-
nation (NOD) task was used to examine attention and memory
in HR and LR rats (Ballaz et al., 2007b). LR showed increased
exploration of new objects compared to old objects, whereas
HR spent the same amount of time exploring new vs. old
objects (Ballaz et al., 2007b). Interestingly, prolonged exposure
to alcohol has been shown to impair cognitive functions such
as attention and memory, and to produce perseveration which
is the tendency to continue an activity after the cessation of
the original stimulus (Ridley, 1994). Systemic administration
of SB269970, a 5-HT7R antagonist, decreased LR exploration
of novel objects but did not alter the behavior of HR rats,
suggesting that activation of 5-HT7Rs may play an important
role in cognitive behaviors such as attention and memory. A
knockout mouse study showed that mice without 5-HT7Rs
had similar performance in the novel object recognition as
that of 5-HT7+/+ mice, but they did exhibit reduced novel
location (spatial) recognition (Hedlund, 2009; Sarkisyan and
Hedlund, 2009). These authors also reported that administration
of SB269970, a 5-HT7R antagonist, also reduced location novelty
recognition compared with vehicle-treated mice. Overall, the
genetic and pharmacological manipulation of 5-HT7Rs provide
further evidence that these receptors may be involved in spe-
cific cognitive processes such as attention and location-related
memory.
Impulsivity is associated with a loss of behavioral control,
which is a prominent trait of attention deficit hyperactivity disor-
der (ADHD) and can be readily observed in rat models of ADHD
(Russell et al., 2000). The transition from moderate alcohol
consumption to excessive alcohol consumption has been hypoth-
esized to be based upon a “loss of control,” with reports suggesting
that the development and course of alcohol use and dependence
is complicated by heightened impulsivity (Miller, 1991; Dom
et al., 2006a,b). In particular, impulsivity may be involved in
dysregulated alcohol-seeking behavior, relapse and the mainte-
nance of voluntary abstinence (Noel et al., 2007). Leo et al. (2009)
investigated the involvement of 5-HT7Rs in an animal model of
impulsivity that used a delayed reward task. Results from their
study (Leo et al., 2009) led them to hypothesize that 5-HT7Rs play
an important role in reward-devaluation processes. These authors
also found that administration of the drug methylphenidate
(MPD) to rats during adolescence reduced “impulsive” behav-
iors in adulthood (Leo et al., 2009). Moreover, MPD can increase
5htr7 mRNA expression in the PFC and ACB (Shell and Core),
which are key structures in the MCL reward pathway (Leo et al.,
2009). In addition, activation of 5-HT7Rs significantly increased
neurite length in striatal neuron primary cultures thus suggesting
a role for 5-HT7Rs in neuroplasticity (Leo et al., 2009; Matthys
et al., 2011). Adriani et al. (2006) also showed that MPD induced
an upregulation of 5htr7 mRNA expression in the striatum (c.f.,
Hedlund, 2009). Therefore, it is possible that 5-HT7R activity
could suppress impulsive behaviors by promoting neuronal dif-
ferentiation in the striatum or other brain regions mediating this
behavior (Matthys et al., 2011). Pharmacological data showed that
SB-269970 counteracted the effects of MPD leading to an increase
in impulsive behaviors, whereas 8-OH-DPAT, a 5-HT7R agonist,
reduced impulsive behavior in naïve adolescent and adult rats
(Leo et al., 2009), again suggesting that 5-HT7Rs are involved in
behavioral self-regulation.
A follow up study using pharmacologic magnetic resonance
imaging (phMRI), with SB2690970 and 8-OH-DPAT, found that
SB269970 produced a direct and highly selective 5-HT7R block-
ade in a specific neurocircuit composed of orbital prefrontal
cortex (oPFC)-to-ACB projections; whereas 8-OH-DPAT gener-
ated a wide spread effect from the dorsal striatum to the medial
prefrontal cortex (mPFC) (Canese et al., 2011). These findings
provided further evidence that 5-HT7Rs are located within sub-
regions of the MCL reward pathway. In addition, it suggests
that two distinct serotonergic sub-pathways may be involved in
5-HT7R activity within theMCL. Collectively, these findings indi-
cate that 5-HT7R activity mediates, at least in part, behavioral
self-control further implicating the 5-HT7R as a novel target to
reduce maladaptive behaviors associated with alcohol and drug
addiction.
There have been a limited number of studies investigating
a possible association between 5-HT7Rs and alcohol addiction.
Human genetic studies have implicated a 5htr7 polymorphism in
a genetic predisposition to develop alcohol dependence (Zlojutro
et al., 2011: Kim et al., 2014). Event-related brain oscillations
(EROs) are considered to be highly heritable neurophysiologi-
cal correlates of human perception and cognitive performance
with marked deficits displayed in various psychiatric disorders
(Zlojutro et al., 2011). ERO deficits have been found among
alcohol-dependent and individuals at high-risk to develop this
disorder, and these deficits are thought to precede the devel-
opment of alcoholism Rangaswamy and Porjesz, 2008; Zlojutro
et al., 2011. Thus, these authors propose that ERO deficits may
serve as an effective endophenotype for alcohol dependence
(Zlojutro et al., 2011). Zlojutro et al. (2011) found a 5htr7 poly-
morphism (the gene is located on chromosome 10q23) that
was associated with altered EROs, suggesting that serotonergic
activity is involved in the neurophysiological underpinnings of
theta EROs. In addition, their findings indicated that this par-
ticular 5htr7 polymorphism was associated with (a) an alcohol
dependence diagnosis (DSM IV) among case-controls as well
as (b) theta ERO reductions among homozygotes for alcohol
dependence in both case-control and family-based samples.
In another study, Kim et al. (2014) wanted to replicate the find-
ings of Zlojutro et al. (2011). Their results were consistent with
Zlojutro et al. (2011) and indicated that a 5htr7 polymorphism
is also associated with the Alcohol Use Disorders Identification
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Test (AUDIT) which is considered to be a reliable and widely used
screening scale for the early detection of alcohol consumption,
alcohol dependence, and problems related to drinking (Saunders
et al., 1993). Several 5htr7 haplotypes were found to have strong
associations with alcohol dependence based on the AUDIT (Kim
et al., 2014). In addition, an extensive review of previous find-
ings of genome-wide association studies (GWASs) of alcohol
dependence as well as meta-analyses, cis-acting expression of
quantitative locus (cis-eQTL) analyses, rat brain transcriptome
analyses, bioinformatics analyses and SNP disease association
analyses provided further evidence that 5htr7 polymorphisms are
likely involved in the risk of alcohol dependence (Zuo et al., 2014).
There is some preclinical evidence that exposure to alcohol
vapors can enhance 5-HT7R expression in the brain. Yoshimoto
et al. (2012) demonstrated that a single day of alcohol vapor-
exposure significantly increased 5htr7 mRNA in the lateral
hypothalamus of C57BL/6J mice, while 20 days of exposure
enhanced 5htr7 mRNA expression in the ACB and caudate puta-
men as well. However, antagonism of 5-HT7Rs with SB269970
did not alter alcohol drinking behavior in the animals exposed to
alcohol vapor (Yoshimoto et al., 2012). Although the SB269970
did not block alcohol drinking in this particular animal model,
it does not rule out 5-HT7R involvement in alcohol addiction
behaviors. Utilizing different animal models, different 5-HT7R
antagonists (as well as agonists), and/or examining other behav-
iors such as alcohol-seeking, relapse or reinforcementmay reveal a
role for 5-HT7Rs in a predisposition for, and/or the development
of, alcohol addiction.
CONCLUSION
The 5-HT system plays an important role in behaviors associated
with addiction processes. Accumulating evidence from multiple
disciplines suggests that the 5-HT7R may be involved in vari-
ous aspects of drug and alcohol consumption as well as reward
and reinforcement. The location and neurochemical properties
of 5HT7Rs implicate an important role for this receptor in alco-
hol and drug abuse/dependence. Additional studies are needed
to determine the potential that the 5-HT7R holds as a possible
molecular target for the treatment of alcohol and drug addiction.
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